A cure rate survival model under a hybrid latent activation scheme

In lifetimes studies, the occurrence of an event (such as tumor detection or death) might be caused by one of many competing causes. Moreover, both the number of causes and the time-to-event associated with each cause are not usually observable. The number of causes can be zero, corresponding to a cure fraction. In this article, we propose a method of estimating the numerical characteristics of unobservable stages (such as initiation, promotion and progression) of carcinogenesis from data on tumor size at detection in the presence of latent competing causes. To this end, a general survival model for spontaneous carcinogenesis under a hybrid latent activation scheme has been developed to allow for a simple pattern of the dynamics of tumor growth. It is assumed that a tumor becomes detectable when its size attains some threshold level (proliferation of tumorais cells (or descendants) generated by the malignant cell), which is treated as a random variable. We assume the number of initiated cells and the number of malignant cells (competing causes) both to follow weighted Poisson distributions. The advantage of this model is that it incorporates into the analysis characteristics of the stage of tumor progression as well as the proportion of initiated cells that had been ‘promoted’ to the malignant ones and the proportion of malignant cells that die before tumor induction. The lifetimes corresponding to each competing cause are assumed to follow a Weibull distribution. Parameter estimation of the proposed model is discussed through the maximum likelihood estimation method. A simulation study has been carried out in order to examine the coverage probabilities of the confidence intervals. Finally, we illustrate the usefulness of the proposed model by applying it to a real data involving malignant melanoma.

[1]  R. Kay The Analysis of Survival Data , 2012 .

[2]  Narayanaswamy Balakrishnan,et al.  Destructive weighted Poisson cure rate models , 2011, Lifetime data analysis.

[3]  V. Cancho,et al.  A note on a unified approach for cure rate models , 2010 .

[4]  Narayanaswamy Balakrishnan,et al.  COM–Poisson cure rate survival models and an application to a cutaneous melanoma data , 2009 .

[5]  Josemar Rodrigues,et al.  On the unification of long-term survival models , 2009 .

[6]  R. Écochard,et al.  Promotion Time Models with Time‐Changing Exposure and Heterogeneity: Application to Infectious Diseases , 2008, Biometrical journal. Biometrische Zeitschrift.

[7]  Narayanaswamy Balakrishnan,et al.  Connections of the Poisson weight function to overdispersion and underdispersion , 2008 .

[8]  Bradley P Carlin,et al.  Flexible Cure Rate Modeling Under Latent Activation Schemes , 2007, Journal of the American Statistical Association.

[9]  Joseph G. Ibrahim,et al.  Cure rate models: A unified approach , 2005 .

[10]  Marta Pérez-Casany,et al.  Overdispersed and underdispersed Poisson generalizations , 2005 .

[11]  R. Rigby,et al.  Generalized additive models for location, scale and shape , 2005 .

[12]  Joseph G Ibrahim,et al.  A General Class of Bayesian Survival Models with Zero and Nonzero Cure Fractions , 2005, Biometrics.

[13]  Sudhir Paul,et al.  Bias-corrected maximum likelihood estimator of the negative binomial dispersion parameter. , 2005, Biometrics.

[14]  T. Minka,et al.  A useful distribution for fitting discrete data: revival of the Conway–Maxwell–Poisson distribution , 2005 .

[15]  Joseph G. Ibrahim,et al.  Bayesian Survival Analysis , 2004 .

[16]  Bradley P Carlin,et al.  Parametric Spatial Cure Rate Models for Interval‐Censored Time‐to‐Relapse Data , 2004, Biometrics.

[17]  J. Ibrahim,et al.  Bayesian Inference for Multivariate Survival Data with a Cure Fraction , 2002 .

[18]  Chin-Shang Li,et al.  Identifiability of cure models , 2001 .

[19]  Ana Maria Barral,et al.  Immunological Studies in Malignant Melanoma : Importance of TNF and the Thioredoxin System , 2001 .

[20]  Jim E. Griffin,et al.  A Bayesian Partition Model for Customer Attrition , 2001 .

[21]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. P. Sy,et al.  Estimation in a Cox Proportional Hazards Cure Model , 2000, Biometrics.

[23]  F Louzada-Neto,et al.  Polyhazard Models for Lifetime Data , 1999, Biometrics.

[24]  Joseph G. Ibrahim,et al.  A New Bayesian Model For Survival Data With a Surviving Fraction , 1999 .

[25]  R. Gunst Applied Regression Analysis , 1999, Technometrics.

[26]  Marta Pérez-Casany,et al.  Weighted Poisson Distributions for Overdispersion and Underdispersion Situations , 1998 .

[27]  N. Draper,et al.  Applied Regression Analysis: Draper/Applied Regression Analysis , 1998 .

[28]  A D Tsodikov,et al.  A distribution of tumor size at detection: an application to breast cancer data. , 1997, Biometrics.

[29]  A Stochastic Model of Carcinogenesis and Tumor Size at Detection , 1997, Advances in Applied Probability.

[30]  Peter K. Dunn,et al.  Randomized Quantile Residuals , 1996 .

[31]  A Y Yakovlev,et al.  A distribution of tumor size at detection and its limiting form. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Yakovlev,et al.  Stochastic Models of Tumor Latency and Their Biostatistical Applications , 1996 .

[33]  A. Yakovlev,et al.  A diversity of responses displayed by a stochastic model of radiation carcinogenesis allowing for cell death. , 1996, Mathematical biosciences.

[34]  W. D. Ray 4. Modelling Survival Data in Medical Research , 1995 .

[35]  D. Collett Modelling Survival Data in Medical Research , 1994 .

[36]  A D Tsodikov,et al.  A stochastic model of hormesis. , 1993, Mathematical biosciences.

[37]  Pranab Kumar Sen,et al.  Large Sample Methods in Statistics: An Introduction with Applications , 1993 .

[38]  S T Rachev,et al.  A stochastic model of radiation carcinogenesis: latent time distributions and their properties. , 1993, Mathematical biosciences.

[39]  J J Shuster,et al.  Parametric versus non-parametric methods for estimating cure rates based on censored survival data. , 1992, Statistics in medicine.

[40]  A. Kopp-Schneider,et al.  The application of a multistage model that incorporates DNA damage and repair to the analysis of initiation/promotion experiments. , 1991, Mathematical biosciences.

[41]  W. Piegorsch Maximum likelihood estimation for the negative binomial dispersion parameter. , 1990, Biometrics.

[42]  N. Gordon,et al.  Application of the theory of finite mixtures for the estimation of 'cure' rates of treated cancer patients. , 1990, Statistics in medicine.

[43]  Vernon T. Farewell,et al.  Mixture models in survival analysis: Are they worth the risk? , 1986 .

[44]  D. A. Preece,et al.  The negative binomial distribution , 1985 .

[45]  A I Goldman,et al.  Survivorship analysis when cure is a possibility: a Monte Carlo study. , 1984, Statistics in medicine.

[46]  V. Farewell,et al.  The use of mixture models for the analysis of survival data with long-term survivors. , 1982, Biometrics.

[47]  C. R. Rao,et al.  On discrete distributions arising out of methods of ascertainment , 1965 .

[48]  Joseph Berkson,et al.  Survival Curve for Cancer Patients Following Treatment , 1952 .

[49]  Feller William,et al.  An Introduction To Probability Theory And Its Applications , 1950 .

[50]  R. Fisher THE EFFECT OF METHODS OF ASCERTAINMENT UPON THE ESTIMATION OF FREQUENCIES , 1934 .